Saad Z. Usmani, MD, MBA, FACP
Dr. Usmani is Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center in New York.
Articles by Saad Z. Usmani, MD, MBA, FACP
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
The panelists highlight key data presented at ASCO 2023.
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
The panel considers triplet versus quadruplet therapy for myeloma induction.
Thomas G. Martin, MD, and Saad Z. Usmani, MD, MBA, FACP, debate CAR-T vs bispecific antibodies for R/R MM.
Amrita Krishnan, MD, FACP, and Saad Z. Usmani, MD, MBA, FACP, debate if CAR-T therapy will replace AHSCT in multiple myeloma.
Experts focus on the latest news and clinical development and impact for multiple myeloma.
Experts discuss treatment options related to anti-CD38 based combination triplets.
Drs. Saad Usumani and Sydney Lu discuss adjusting multiple myeloma treatments to the realities of the COVID-19 pandemic.
Communication, clarity, patient education, and support from the healthcare team can all contribute to adherence to therapy.
Janssen and Legend Biotech announced new data for BCMA-directed CAR-T cell therapy cilta-cel for relapsed/refactory MM.
Based on the LLS Professional Education Webcast: Multiple Myeloma: Diagnosis, Treatment, and Side Effects Management ...
Dr. Usmani discusses an indirect treatment comparison study which assesses daratumumab plus lenalidomide and dexamethasone.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.